Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

APPY 1.72 +0.03 (1.78%)
price chart
Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session
Venaxis, Inc. was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session - Tale of the Tape  Digital Journal
Related articles »  
Venaxis, Inc. (APPY) Presents APPY1 Test Data at ACEP14
Venaxis, Inc. (NASDAQ: APPY) announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ...  MarketWatch
Related articles »  
Stock Highlights: Digital Ally Inc. (DGLY), Viggle Inc. (VGGL), Venaxis, Inc ...
Digital Ally Inc. (DGLY) of the Technology sector lost -2.17% yesterday with a volume of 1,287,874 shares and volatility this week of 9.88%.
Related articles »  
Morning Most Volatile : The Dixie Group, Inc. (DXYN), Venaxis, Inc. (APPY ...
The Dixie Group, Inc. (DXYN) of the Industrial Goods sector has gained 5.55% from opening today with a volume of 38,437 shares and volatility this week of 8.08%.
Venaxis: Latest Clinical Data Reveals Huge Market Potential (APPY)
Venaxis Inc. recently reported detailed data of the clinical pathways undertaken by the pediatric patients enrolled in their pivotal trial.
Venaxis Inc (APPY) news: What Every Investor Needs To Know About Venaxis, Inc.
If we were Venaxis, Inc., how would we stage this cutoff? Considering appendicitis is dangerous if left unchecked, it is obvious that we want to minimize the number of people with appendicitis who can potentially slip through this cutoff.
UPDATE: Aegis Capital Lowers PT on Venaxis Following Recent Dilution
In the report, Aegis Capital noted, �We are reducing our price target on Venaxis, Inc. due to the dilution that occurred in the wake of the firm's most recently-completed financing.
Venaxis Inc (APPY): Increase In Institutional Ownership, Q4 Catalyst Make ...  Seeking Alpha
Aegis Maintains Venaxis (APPY) at Buy, Cuts PT to $3.50 Following Recent ...  StreetInsider.com (subscription)
Related articles »  
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies ...
CASTLE ROCK, Colo., Nov. 13, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children ...
Related articles »  
Venaxis Inc (APPY) news: Venaxis's Pivotal Data Due In March
In two recent studies, Castle Rock, CO-based Venaxis found that the percentage of patients suspected of appendicitis, who received CT scans, was nearly identical in both the lower-to-moderate and high-risk groups.
Related articles »  
Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals ...
Venaxis (NASDAQ:APPY) is a diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test.